Improving patient safety for better health outcomes

Assuring the safety of medicines and health products doesn’t stop once they’re approved for market use. Monitoring and surveillance of a product’s safety – also known as pharmacovigilance – is important in detecting rare and serious side effects that may not be observed in clinical trials.

Effective pharmacovigilance programs are critical to strong regulatory systems and support effective regulatory responses that protect patients from potential harm. We work to strengthen pharmacovigilance programs to ensure the continued safety of medicines, vaccines, and other medical products; optimize treatment regimens; and support data-driven decision making.

Reporting adverse events for COVID-19 medical products

With the increasing availability of COVID-19 vaccines and treatments comes an equally urgent need for surveillance systems to monitor their continued safety. Through the Promoting the Quality of Medicines Plus (PQM+) program, funded by the U.S. Agency of International Development (USAID), we’re working with national medicines regulators in Burkina Faso, Ethiopia, Ghana, Kazakhstan, Pakistan, and Uzbekistan to improve pharmacovigilance and ensure safe, effective, quality vaccines for patients.

Related content 

Strengthening medicines regulatory systems

Strong regulatory systems protect consumers from poor-quality medicines and help ensure the health and well-being of millions of patients.

Learn More

Expanding manufacturing capacity

Producing medicines closer to patients builds supply chain resilience and improves health equity.

Learn More

Bolstering public health laboratory networks

Strong laboratory systems help doctors make informed treatment decisions, empower regulators to act, and support researchers to quickly identify new diseases.

Learn more

newsletter sign-up

Get the latest updates on global health projects.

Sign up for our newsletter